Stock Ratings / Health Care / CRSP / forecast

LLY (72) JNJ (66) ABBV (71) UNH (70) ⌘ Pro Terminal →

CRISPR Therapeutics AG (CRSP) 12-Month Stock Forecast & Price Target Cone

$54.26 +0.28% NASDAQ • Public Delayed / 60s Snapshot

CRISPR Therapeutics AG (CRSP) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (55/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+61.2% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.

ROARABLE D+ • SELL / AVOID Cap $5.25B

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

5-PILLAR SNOWFLAKE RADARRw D · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-1.3% Base Target

WHALE OPTIONS TUG-OF-WAR:55% Call Buyers ($2.5M)

45% PutsMax Pain: $53.00

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CRSP Position Size: $10,000

Shares at $54.26: 184.3 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $41.75

$7,694

$-2,306 (-23.1%)

12M Consensus BaseTarget $53.53

$9,865

$-135 (-1.3%)

12M Bull Case BreakoutTarget $67.98

$12,529

+$2,529 (+25.3%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (32 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 6

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$56	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$64	69%	B
JP MorganUS Large-Cap Research	SELL	$48	58%	C

🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk

Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CRSP)

✓Live walkthrough of CRSP's RQD Radar, SEC cash-conversion gap & downside levels
✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
✓Includes instant 24/7 email alert whenever any of your stocks flip to Red

RQD INSIDER CLUB UPGRADE$49/YEAR

Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?

🤖 Try AI Indicator Builder ($49/yr VIP) →$100K Arena

CRSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.76%📐 WEDGE COMPRESSION COIL

2026-10-30O $53.27H $54.10L $50.60C $51.42VOL 1.17M

RES: $59.61SUP: $47.56SMA50: $54.19SMA200: $52.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRSP Butterfly Map → + Track CRSP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

21.4%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRSP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRSP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

CRSP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CRSP's 12-month stock price target?

CRISPR Therapeutics AG (CRSP) carries a 12-month consensus base price target of $53.53 (-1.3% from $54.26), with a bull-case target of $67.98 and a bear-case floor of $41.75.

Is CRSP stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates CRSP D+ (Sell — SELL) with an RQD Confidence score of 55/100.

Direct Sub-Reports: CRSP RQD Cockpit CRSP 12M Forecast CRSP Earnings & Move CRSP Dividends & DRIP CRSP Insiders & 13F CRSP Whale Options CRSP Profit Sankey CRSP News & Why